Michael Migden

Checkpoint inhibitor shrinks advanced squamous cell skin cancer

Michael Migden, M.D.

MD Anderson-led clinical trial shows nearly 50 percent of patients respond to cemiplimab HOUSTON – Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of patients with […]